Clinical Trial

Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma

Name: Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma — clinical trial record (NCT07236528)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is a prospective, multicenter, single arm, open label study aimed at evaluating the efficacy and safety of the combination of Carilizumab, Apatinib Mesylate, and first-line radiotherapy for advanced mucosal melanoma.

Trial Details

NCT Number	NCT07236528
Lead Sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions	Mucosal Melanoma
Enrollment	30 participants
Start Date	2025-11-30
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-05-31 (estimated)
Updated on ClinicalTrials.gov	2025-11-19